Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. More info.
Mr. Anthony A. Lombardo, also known as Tony, has been Interim Chief Executive Officer at Advaxis, Inc., since July 6, 2017. Mr. Lombardo served as Chief Business Officer at Advaxis, Inc., from April 2017 to July 6, 2017 and its Executive Vice President from May 9, 2017 to July 6, 2017. Mr. Lombardo served as Senior Vice President at Advaxis, Inc., since April 2017 until May 9, 2017. Since April 2000, Mr. Lombardo served as the President and Chief Executive Officer of E-Z-EM Inc., which was sold to Bracco Diagnostics in 2008, where Mr. Lombardo remained and oversaw business operations for six years as the Chief Operating Officer.. Prior to joining E-Z-EM Inc., Mr. Lombardo served as President of ALI Imaging Systems Inc. (a full-service provider of radiology information and image management systems) from 1998 to 2000. From 1996 to 1998, Mr. Lombardo served as Global Manager of the Integrated Imaging Systems business of General Electric Medical Systems. He also headed divisions of Loral and Lockheed Martin Corp. from 1994 to 1996, Sony Corporation from 1990 to 1994 and Philips Medical Systems from 1979 to 1990. He has also held leadership roles at General Electric Medical Systems, Philips Medical Systems, Loral/Lockheed Martin Corp. and Sony Corporation. He was Partner as The Channel Group, where he provided strategic advisory services to biotechnology, pharma and med-tech companies from 2014 to 2017. Mr. Lombardo is an executive with more than 30 years of experience in the medical device industry and related industries. He served as a Director of PointDx Inc. Mr. Lombardo served as a Director of E-Z-EM Inc., since 2000. Mr. Lombardo served as Director of Advanced BioPhotonics Inc., (Formerly, Omnicorder Technologies Inc.) from January 2004 to June 26, 2006. He also served as a Director of OmniCorder since August 2003 and Director of Promos Inc., since January 2004. He serves as Chairman of the Advisory Board of Morristown Medical Center, a part of Atlantic Health System Hospitals. Mr. Lombardo has been honored by the American College of Radiology and the Society of Abdominal Radiology for his years of service to the clinical community. He received a B.S. degree in Biology from St. Francis College and an M.S. degree in Physiology from Duquesne University.
Average tenure and age of the Advaxis management team in years:
Average tenure and age of the Advaxis board of directors in years:
Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. … However, the future seems brighter, as analysts expect an industry-beating growth rate of 24.42% in the upcoming year. … If Advaxis has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.Simply Wall St - – Full article
ADXS, with its market capitalisation of US$112.65M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect ADXS to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.Simply Wall St - – Full article
NasdaqGS:ADXS Insider_trading Mar 9th 18 General Public Ownership A substantial ownership of 58.47% in ADXS is held by the general public. … Public Company Ownership Another group of owners that a potential investor in ADXS should consider are other public companies, with a stake of 5.95%. … With this size of ownership in ADXS, this ownership class can affect the company's business strategy.Simply Wall St - – Full article
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time. … See our latest analysis for Advaxis Was ADXS's recent earnings decline worse than the long-term trend and the industry? … For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.Simply Wall St - – Full article
Check out our latest analysis for Advaxis ADXS is bordering on breakeven, according to analysts. … How fast will ADXS have to grow each year in order to reach the breakeven point by 2022? … Next Steps: There are too many aspects of ADXS to cover in one brief article, but the key fundamentals for the company can all be found in one place – ADXS’s company page on Simply Wall St.Simply Wall St - – Full article
However, this is still an improvement on its past 5-year earnings growth rate of -37.04%, on average. … I've plotted out each year's earnings expectations and inserted a line of best fit to calculate an annual growth rate from the slope in order to understand the overall trajectory of ADXS's earnings growth over these next few years. … NasdaqGS:ADXS Future Profit Jan 5th 18 By 2021, ADXS's earnings should reach $-82.7M, from current levels of $-93.4M, resulting in an annual growth rate of 33.24%.Simply Wall St - – Full article
Advaxis Inc's (NASDAQ:ADXS) latest earnings update in October 2017 showed company earnings became less negative compared to the previous year's level - great news for investors Today I want to provide a brief commentary on how market analysts predict Advaxis's earnings growth trajectory over the next few years and whether the future looks brighter. … See our latest analysis for Advaxis Market analysts' consensus outlook for this coming year seems pessimistic, with earnings becoming even more negative, generating $-115.0M in 2018. … NasdaqGS:ADXS Future Profit Dec 28th 17 Even though it is useful to be aware of the growth each year relative to today’s value, it may be more beneficial estimating the rate at which the earnings are moving on average every year.Simply Wall St - – Full article
The direct benefit for Advaxis Inc (NASDAQ:ADXS), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … See our latest analysis for Advaxis Is ADXS right in choosing financial flexibility over lower cost of capital? … Choosing financial flexibility over capital returns make sense if ADXS is a high-growth company.Simply Wall St - – Full article
The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run. … In the previous year, the industry saw growth of 8.45%, though still underperforming the wider US stock market. … ADXS lags the pack with its negative growth rate of -20.11% over the past year, which indicates the company will be growing at a slower pace than its biotech peers.Simply Wall St - – Full article
Insider Ownership Another important group of shareholders are company insiders. … NasdaqGS:ADXS Insider Trading Nov 3rd 17 General Public Ownership The general public holds a substantial 41.68% stake in ADXS, making it a highly popular stock among retail investors. … Public Company Ownership Potential investors in ADXS should also look at another important group of investors: other public companies, with a stake of 7.42%, who are primarily invested because of strategic and capital gain interests.Simply Wall St - – Full article
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient’s immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
305 College Road East,
New Jersey, 08540,
|Exchange Symbol||Ticker Symbol||Security||Exchange||Country||Currency||Listed on|
|NasdaqGS||ADXS||Common Shares||Nasdaq Global Select||US||USD||28. Jul 2005|
|Pharmaceuticals & Biotech|
|Company Analysis updated:||2018/03/21 18:43|
|Last estimates confirmation:||2018/03/16|
|Last earnings update:||2018/01/31|
|Last annual earnings update:||2017/10/31|
All dates in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.